Progress in the Molecular Characterization of Prostate Cancer: Implications for the Identification of Novel Biomarkers and Therapeutic Targets
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 11269
Special Issue Editors
Interests: molecular pharmacology of anticancer agents; preclinical development of innovative therapeutic approaches; development of tumor preclinical models (PDXs, 3D-coltures); identification and validation of new biomarkers and therapeutic targets; miRNA-based therapeutics c
Special Issue Information
Dear Colleagues,
Prostate cancer is a disease of great heterogeneity, from both a genomic and clinical point of view. The introduction of next-generation sequencing and the parallel development of computational biology approaches have led to a better understanding of prostate cancer genomic complexity and to an improved definition of disease subtypes characterized by specific genomic alterations. In the field of prostate cancer translational research, great efforts are currently being devoted to the validation of such genomic alterations as potential prognostic/predictive biomarkers and therapeutic targets. In this context, a variety of DNA, RNA, or protein-based tissue biomarkers as well as of circulating biomarkers, including circulating tumor cells and cell-free nucleic acids, have been proposed with the aim of improving prognosis and the selection of therapeutic strategies for specific groups of patients.
The Special Issue “Progress in the Molecular Characterization of Prostate Cancer: Implications for the Identification of Novel Biomarkers and Therapeutic Targets” aims to present molecular studies dealing with the identification and functional characterization of specific molecular alterations mainly involved in disease pathogenesis, progression, and/or treatment response that are suitable for future clinical exploitation towards improving the management of patients.
Dr. Nadia Zaffaroni
Dr. Paolo Gandellini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- next-generation sequencing
- tissue biomarkers (nucleic acid- or protein-based)
- circulating biomarkers (CTCs, ctDNA, miRNAs)
- prognostic and predictive factors
- therapeutic targets
